PMID: 6167820Jul 1, 1981Paper

Bepridil blockade of Ca2+-dependent action potentials in vascular smooth muscle of dog coronary artery

Journal of Cardiovascular Pharmacology
D R Harder, N Sperelakis

Abstract

The effect of the new vasodilatory and antianginal compound, bepridil (CERM-1978), was examined on the electrical activity of the vascular smooth muscle of isolated dog coronary arteries. Tetraethylammonium (10 mM) was used to induce excitability in the muscle in the form of Ca2+-dependent overshooting action potentials, whose inward current is carried almost exclusively by Ca2+ ion through voltage-dependent slow channels. Bepridil (5 X 10(-7)--1 X 10(--5) M) produced a dose-dependent depression of the rate of rise and amplitude of these Ca2+ spikes. Complete blockade of the action potentials occurred at 1 X 10(-5) M bepridil. These effects of bepridil were antagonized by elevation of external Ca2+ concentration ([CA]o). The effects of bepridil were substantially reversed by washout after about 30 min. Bepridil (10(-5) M) also produced a small but significant (p less than 0.05) increase in resting membrane resistance (input resistance increased from a mean of 10.1 to 12.4 m omega), accompanied by a small but significant (p less than 0.05) depolarization of 6 mV (from a mean of --51 to --45 mV). These latter effects are consistent with a diminution of the resting K+ conductance (gK) by bepridil. It is concluded that the vasodila...Continue Reading

Citations

Dec 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·S IshikawaT Itoh
Jul 16, 1982·European Journal of Pharmacology·D C Pang, N Sperelakis
Jan 8, 1985·European Journal of Pharmacology·N ChandR D Sofia
Nov 19, 1986·European Journal of Pharmacology·E WinslowR J Marshall
Jan 7, 2005·Circulation Journal : Official Journal of the Japanese Circulation Society·Yuji NakazatoHiroyuki Daida
Jul 27, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Kohei MiyajiTohru Ohe
Feb 1, 1992·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·W N WuP J O'Neill
Jun 1, 1984·The American Journal of Cardiology·A SassineP Puech
Jun 1, 1988·The American Journal of Cardiology·M K SharmaU Thadani
Jan 25, 1985·The American Journal of Cardiology·B N SinghK Nademanee
Mar 15, 1989·The American Journal of Cardiology·W J RemmeC J Storm
May 1, 1986·British Journal of Pharmacology·P A Molyvdas, N Sperelakis
Apr 9, 1992·The American Journal of Cardiology·B N Singh
Apr 9, 1992·The American Journal of Cardiology·K A NaraharaK F Hossack
Mar 15, 1985·The American Journal of Cardiology·K A NaraharaJ Park
Apr 21, 2010·Experimental Biology and Medicine·Gregory M Dick, Johnathan D Tune
Mar 1, 1985·British Journal of Clinical Pharmacology·A P RaeI Hutton
Apr 1, 1984·Acta Pharmacologica Et Toxicologica·E MikkelsenO L Pedersen
Jan 15, 1983·Biochemical Pharmacology·G Cramb, J W Dow
Mar 1, 1984·Biochemical Pharmacology·D C Pang, N Sperelakis
Apr 15, 1984·Biochemical Pharmacology·A Younes, J M Schneider

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.